CJC-1295 No DAC / Ipamorelin Blend (5mg / 5mg)

Description

CJC-1295 No DAC / Ipamorelin Blend Overview

This blend pairs CJC-1295 No DAC, also written Mod GRF 1-29, with ipamorelin at 5mg of each for 10mg total. CJC-1295 No DAC is a 29 amino acid synthetic analogue of the N-terminal fragment of human growth hormone releasing hormone, modified at four residue positions. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the ghrelin receptor. Neither compound is an approved medicine in Canada or the United States, and the material supplied here is a research chemical. Ipamorelin acetate appears on the United States Food and Drug Administration list of bulk drug substances that may present significant safety risks.

The two act on different pituitary receptors, which is why they are studied as a pair. GHRH analogues act at the GHRH receptor on somatotroph cells, while ghrelin receptor agonists act at GHS-R. Published work in this area is largely in rodents, with GH and IGF-1 concentrations as the measured endpoints. In the rat work that introduced ipamorelin, the GH secretagogues tested did not change plasma FSH, LH, prolactin or TSH, which is the basis for describing ipamorelin as selective.

Technical Specifications

• Peptide Names: CJC-1295 (No DAC) and ipamorelin
• Synonyms: Mod GRF 1-29, modified GRF(1-29), tetrasubstituted GRF(1-29); NNC 26-0161 (ipamorelin)
• CJC-1295 No DAC: CAS 863288-34-0, molecular formula C152H252N44O42, molar mass 3367.9 g/mol
• Ipamorelin: CAS 170851-70-4, molecular formula C38H49N9O5, molar mass 711.85 g/mol
• Ipamorelin sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
• Combined Mass: 10mg total (5mg CJC-1295 No DAC plus 5mg ipamorelin)
• Purity: ≥99.0% (determined by HPLC)
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in sterile water

Research Context
Pathways that have been examined in the published literature include:

• GHRH receptor agonism (CJC-1295 No DAC): GHRH analogues bind the GHRH receptor on anterior pituitary somatotrophs. Studies in this area measure GH transcription and secretion.
• Ghrelin receptor agonism (ipamorelin): Ipamorelin binds GHS-R. Work on ghrelin receptor agonists examines the somatostatin pathway alongside direct stimulation of GH release.
• Combined receptor activation: Studies that give a GHRH analogue together with a ghrelin receptor agonist report larger GH responses in animal models than either compound produced alone. The size of that difference varies between studies.

These are observations in laboratory models and should not be read as describing effects in a person or an animal outside a controlled study.

Storage and Handling

• Lyophilized (powder): Store at minus 20 degrees Celsius, sealed and protected from light and moisture; see the batch documentation for the retest date.
• Reconstituted (liquid): Keep refrigerated at 4 degrees Celsius and protected from light. The retest date in the batch documentation applies to the sealed lyophilized vial only.
• Handling: Standard laboratory safety protocols apply. This product is for laboratory research use only.

Testing and Quality Control
Every batch of this blend is released against the following checks:

1. HPLC: to confirm individual and combined purity profiles of ≥99.0%.
2. MS (mass spectrometry): to confirm the molecular weight and identity of both peptides.
3. Visual verification: to confirm the integrity of the lyophilized cake.

For laboratory research use only. Not for human or veterinary use.

Further reading

• CJC-1295 with DAC vs no DAC
• Tesamorelin vs sermorelin: key differences
• How to store peptides: lyophilized vs reconstituted